Free Trial
NASDAQ:UBX

UNITY Biotechnology Q4 2023 Earnings Report

UNITY Biotechnology EPS Results

Actual EPS
-$0.34
Consensus EPS
-$0.57
Beat/Miss
Beat by +$0.23
One Year Ago EPS
N/A

UNITY Biotechnology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

UNITY Biotechnology Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

UNITY Biotechnology Earnings Headlines

One tiny company just cracked Google’s $19B problem
For decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. Then an MIT team cracked the code… dropping the cost from $63,000 to just 90 cents per gram. Now, one US-based factory is gearing up to supply the AI, aerospace, and EV industries with the one material they can’t continue to grow without. Only one company controls it, and its stock is still flying under Main Street’s radar.tc pixel
UBX Unity Biotechnology, Inc. - Seeking Alpha
See More UNITY Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like UNITY Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on UNITY Biotechnology and other key companies, straight to your email.

About UNITY Biotechnology

UNITY Biotechnology (NASDAQ:UBX), a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

View UNITY Biotechnology Profile

More Earnings Resources from MarketBeat